EdgarLookup

MCCORMICK & CO INC — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that MCCORMICK & CO INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
11.5%
Profit Margin
Net income ÷ revenue
6%
Return on Assets
Net income ÷ assets
1.3x
Debt-to-Equity
Total liabilities ÷ equity
+1.7%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2025 Nov 30, 2025 $6.84B Jan 22, 2026
FY2025 Nov 30, 2024 $6.72B Jan 22, 2026
FY2025 Nov 30, 2023 $6.66B Jan 22, 2026
FY2024 Nov 30, 2022 $6.35B Jan 23, 2025
FY2023 Nov 30, 2021 $6.32B Jan 25, 2024
FY2020 Nov 30, 2020 $1.56B Jan 28, 2021
FY2020 Aug 31, 2020 $1.43B Jan 28, 2021
FY2020 May 31, 2020 $1.40B Jan 28, 2021
FY2020 Feb 29, 2020 $1.21B Jan 28, 2021
FY2020 Nov 30, 2019 $1.48B Jan 28, 2021

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2017 Nov 30, 2017 $1.49B Jan 25, 2018
FY2017 Aug 31, 2017 $1.19B Jan 25, 2018
FY2017 May 31, 2017 $1.11B Jan 25, 2018
FY2017 Feb 28, 2017 $1.04B Jan 25, 2018
FY2017 Nov 30, 2016 $1.23B Jan 25, 2018
FY2017 Aug 31, 2016 $1.09B Jan 25, 2018
FY2017 May 31, 2016 $1.06B Jan 25, 2018
FY2017 Feb 29, 2016 $1.03B Jan 25, 2018
FY2016 Nov 30, 2015 $1.20B Jan 25, 2017
FY2016 Aug 31, 2015 $1.06B Jan 25, 2017

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Nov 30, 2025 $2.59B Jan 22, 2026
FY2025 Nov 30, 2024 $2.59B Jan 22, 2026
FY2025 Nov 30, 2023 $2.50B Jan 22, 2026
FY2024 Nov 30, 2022 $2.27B Jan 23, 2025
FY2023 Nov 30, 2021 $2.49B Jan 25, 2024
FY2020 Nov 30, 2020 $660.70M Jan 28, 2021
FY2020 Aug 31, 2020 $590.30M Jan 28, 2021
FY2020 May 31, 2020 $579.50M Jan 28, 2021
FY2020 Feb 29, 2020 $469.90M Jan 28, 2021
FY2020 Nov 30, 2019 $630.00M Jan 28, 2021

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Nov 30, 2025 $789.40M Jan 22, 2026
FY2025 Nov 30, 2024 $788.50M Jan 22, 2026
FY2025 Nov 30, 2023 $680.60M Jan 22, 2026
FY2024 Nov 30, 2022 $682.00M Jan 23, 2025
FY2023 Nov 30, 2021 $755.30M Jan 25, 2024
FY2020 Nov 30, 2020 $200.70M Jan 28, 2021
FY2020 Aug 31, 2020 $206.10M Jan 28, 2021
FY2020 May 31, 2020 $195.90M Jan 28, 2021
FY2020 Feb 29, 2020 $144.70M Jan 28, 2021
FY2020 Nov 30, 2019 $213.40M Jan 28, 2021

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Nov 30, 2025 $1.07B Jan 22, 2026
FY2025 Nov 30, 2024 $1.06B Jan 22, 2026
FY2025 Nov 30, 2023 $963.00M Jan 22, 2026
FY2024 Nov 30, 2022 $863.60M Jan 23, 2025
FY2023 Nov 30, 2021 $1.02B Jan 25, 2024
FY2020 Nov 30, 2020 $274.90M Jan 28, 2021
FY2020 Aug 31, 2020 $273.00M Jan 28, 2021
FY2020 May 31, 2020 $257.40M Jan 28, 2021
FY2020 Feb 29, 2020 $194.20M Jan 28, 2021
FY2020 Nov 30, 2019 $299.20M Jan 28, 2021

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Nov 30, 2025 $106.10M Jan 22, 2026
FY2025 Nov 30, 2024 $102.90M Jan 22, 2026
FY2025 Nov 30, 2023 $94.90M Jan 22, 2026
FY2024 Nov 30, 2022 $87.50M Jan 23, 2025
FY2023 Nov 30, 2021 $87.30M Jan 25, 2024
FY2022 Nov 30, 2020 $68.60M Jan 26, 2023
FY2021 Nov 30, 2019 $67.30M Jan 27, 2022
FY2020 Nov 30, 2018 $69.40M Jan 28, 2021
FY2019 Nov 30, 2017 $66.10M Jan 28, 2020
FY2018 Nov 30, 2016 $61.00M Jan 25, 2019

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2025 Nov 30, 2025 $1.50B Jan 22, 2026
FY2025 Nov 30, 2024 $1.52B Jan 22, 2026
FY2025 Nov 30, 2023 $1.48B Jan 22, 2026
FY2024 Nov 30, 2022 $1.36B Jan 23, 2025
FY2023 Nov 30, 2021 $1.40B Jan 25, 2024
FY2022 Nov 30, 2020 $1.28B Jan 26, 2023
FY2021 Nov 30, 2019 $1.17B Jan 27, 2022
FY2020 Nov 30, 2018 $1.16B Jan 28, 2021
FY2019 Nov 30, 2017 $1.03B Jan 28, 2020
FY2018 Nov 30, 2016 $1.18B Jan 25, 2019

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Nov 30, 2025 $962.20M Jan 22, 2026
FY2025 Nov 30, 2024 $921.90M Jan 22, 2026
FY2025 Nov 30, 2023 $1.24B Jan 22, 2026
FY2024 Nov 30, 2022 $651.50M Jan 23, 2025
FY2023 Nov 30, 2021 $828.30M Jan 25, 2024
FY2022 Nov 30, 2020 $1.04B Jan 26, 2023
FY2021 Nov 30, 2019 $946.80M Jan 27, 2022
FY2020 Nov 30, 2018 $821.20M Jan 28, 2021
FY2019 Nov 30, 2017 $815.30M Jan 28, 2020
FY2018 Nov 30, 2016 $658.10M Jan 25, 2019

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2022 Nov 30, 2022 $262.00M Jan 26, 2023
FY2022 Nov 30, 2021 $278.00M Jan 26, 2023
FY2022 Nov 30, 2020 $225.30M Jan 26, 2023
FY2021 Nov 30, 2019 $173.70M Jan 27, 2022
FY2020 Nov 30, 2018 $169.10M Jan 28, 2021
FY2019 Nov 30, 2017 $182.40M Jan 28, 2020
FY2018 Nov 30, 2016 $153.80M Jan 25, 2019
FY2017 Nov 30, 2015 $128.40M Jan 25, 2018
FY2016 Nov 30, 2014 $132.70M Jan 25, 2017
FY2015 Nov 30, 2013 $99.90M Jan 28, 2016

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Nov 30, 2025 $13.20B Jan 22, 2026
FY2025 Nov 30, 2024 $13.07B Jan 22, 2026
FY2025 Nov 30, 2023 $12.86B Jan 22, 2026
FY2024 Nov 30, 2022 $13.12B Jan 23, 2025
FY2023 Nov 30, 2021 $12.91B Jan 25, 2024
FY2022 Nov 30, 2020 $12.09B Jan 26, 2023
FY2021 Nov 30, 2019 $10.36B Jan 27, 2022
FY2020 Nov 30, 2018 $10.26B Jan 28, 2021
FY2019 Nov 30, 2017 $10.39B Jan 28, 2020
FY2018 Nov 30, 2016 $4.64B Jan 25, 2019

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Nov 30, 2025 $7.43B Jan 22, 2026
FY2025 Nov 30, 2024 $7.75B Jan 22, 2026
FY2024 Nov 30, 2023 $7.78B Jan 23, 2025
FY2023 Nov 30, 2022 $8.43B Jan 25, 2024
FY2022 Nov 30, 2021 $8.48B Jan 26, 2023
FY2021 Nov 30, 2020 $8.15B Jan 27, 2022
FY2020 Nov 30, 2019 $6.91B Jan 28, 2021
FY2019 Nov 30, 2018 $7.07B Jan 28, 2020
FY2018 Nov 30, 2017 $7.81B Jan 25, 2019
FY2017 Nov 30, 2016 $3.00B Jan 25, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Nov 30, 2025 $5.74B Jan 22, 2026
FY2025 Nov 30, 2024 $5.29B Jan 22, 2026
FY2024 Nov 30, 2023 $5.06B Jan 23, 2025
FY2023 Nov 30, 2022 $4.68B Jan 25, 2024
FY2022 Nov 30, 2021 $4.41B Jan 26, 2023
FY2021 Nov 30, 2020 $3.93B Jan 27, 2022
FY2020 Nov 30, 2019 $3.44B Jan 28, 2021
FY2019 Nov 30, 2018 $3.17B Jan 28, 2020

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Nov 30, 2025 $5.30B Jan 22, 2026
FY2025 Nov 30, 2024 $5.23B Jan 22, 2026
FY2024 Nov 30, 2023 $5.26B Jan 23, 2025
FY2023 Nov 30, 2022 $5.21B Jan 25, 2024
FY2022 Nov 30, 2021 $5.34B Jan 26, 2023
FY2021 Nov 30, 2020 $4.99B Jan 27, 2022
FY2020 Nov 30, 2019 $4.51B Jan 28, 2021
FY2019 Nov 30, 2018 $4.53B Jan 28, 2020
FY2018 Nov 30, 2017 $4.49B Jan 25, 2019
FY2017 Nov 30, 2016 $1.77B Jan 25, 2018

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Nov 30, 2025 $3.82B Jan 22, 2026
FY2025 Nov 30, 2024 $3.55B Jan 22, 2026
FY2024 Nov 30, 2023 $3.25B Jan 23, 2025
FY2023 Nov 30, 2022 $3.02B Jan 25, 2024
FY2022 Nov 30, 2021 $2.78B Jan 26, 2023
FY2021 Nov 30, 2020 $2.42B Jan 27, 2022
FY2020 Nov 30, 2019 $2.06B Jan 28, 2021
FY2019 Nov 30, 2018 $1.76B Jan 28, 2020
FY2018 Nov 30, 2017 $1.17B Jan 25, 2019
FY2017 Nov 30, 2016 $1.06B Jan 25, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Nov 30, 2025 $95.90M Jan 22, 2026
FY2025 Nov 30, 2024 $186.10M Jan 22, 2026
FY2024 Nov 30, 2023 $166.60M Jan 23, 2025
FY2023 Nov 30, 2022 $334.00M Jan 25, 2024
FY2022 Nov 30, 2021 $351.70M Jan 26, 2023
FY2021 Nov 30, 2020 $423.60M Jan 27, 2022
FY2021 Nov 30, 2019 $155.40M Jan 27, 2022
FY2021 Nov 30, 2018 $96.60M Jan 27, 2022
FY2020 Nov 30, 2017 $186.80M Jan 28, 2021
FY2019 Nov 30, 2016 $118.40M Jan 28, 2020

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2025 Nov 30, 2025 $3.61B Jan 22, 2026
FY2025 Nov 30, 2024 $3.86B Jan 22, 2026
FY2024 Nov 30, 2023 $4.14B Jan 23, 2025
FY2023 Nov 30, 2022 $3.91B Jan 25, 2024
FY2022 Nov 30, 2021 $4.74B Jan 26, 2023
FY2021 Nov 30, 2020 $4.02B Jan 27, 2022
FY2020 Nov 30, 2019 $3.72B Jan 28, 2021
FY2019 Nov 30, 2018 $4.14B Jan 28, 2020
FY2018 Nov 30, 2017 $4.77B Jan 25, 2019
FY2017 Nov 30, 2016 $1.06B Jan 25, 2018

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Nov 30, 2025 2 Jan 22, 2026
FY2025 Nov 30, 2024 2 Jan 22, 2026
FY2025 Nov 30, 2023 2 Jan 22, 2026
FY2024 Nov 30, 2022 2 Jan 23, 2025
FY2023 Nov 30, 2021 2 Jan 25, 2024
FY2020 Nov 30, 2020 0 Jan 28, 2021
FY2020 Aug 31, 2020 0 Jan 28, 2021
FY2020 May 31, 2020 0 Jan 28, 2021
FY2020 Feb 29, 2020 0 Jan 28, 2021
FY2020 Nov 30, 2019 0 Jan 28, 2021

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Nov 30, 2025 2 Jan 22, 2026
FY2025 Nov 30, 2024 2 Jan 22, 2026
FY2025 Nov 30, 2023 2 Jan 22, 2026
FY2024 Nov 30, 2022 2 Jan 23, 2025
FY2023 Nov 30, 2021 2 Jan 25, 2024
FY2020 Nov 30, 2020 0 Jan 28, 2021
FY2020 Aug 31, 2020 0 Jan 28, 2021
FY2020 May 31, 2020 0 Jan 28, 2021
FY2020 Feb 29, 2020 0 Jan 28, 2021
FY2020 Nov 30, 2019 0 Jan 28, 2021

Dividends Paid

Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.

Fiscal Year Period End Value Filed
FY2025 Nov 30, 2025 $483.00M Jan 22, 2026
FY2025 Nov 30, 2024 $451.00M Jan 22, 2026
FY2025 Nov 30, 2023 $418.50M Jan 22, 2026
FY2024 Nov 30, 2022 $396.70M Jan 23, 2025
FY2023 Nov 30, 2021 $363.30M Jan 25, 2024
FY2022 Nov 30, 2020 $330.10M Jan 26, 2023
FY2021 Nov 30, 2019 $302.20M Jan 27, 2022
FY2020 Nov 30, 2018 $273.40M Jan 28, 2021
FY2019 Nov 30, 2017 $237.60M Jan 28, 2020
FY2018 Nov 30, 2016 $217.80M Jan 25, 2019